BioCentury
ARTICLE | Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

August 31, 2018 6:20 PM UTC

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd. (SZSE:002422).

Kelun-Biotech could receive up to $350 million from Harbour, which includes an undisclosed upfront payment and milestones. Kelun-Biotech is also eligible for royalties. Neither company responded to inquiries regarding the deal...